Overview

A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This phase I open label study is conducted to assess the potential pharmacokinetic interaction of Raxone® with midazolam in healthy male volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Santhera Pharmaceuticals
Treatments:
Idebenone
Midazolam
Ubiquinone